KEAP1 and Alport syndrome: Overall, these results provide a comprehensive insight into the ameliorative effect of Nrf2 in Alport syndrome and may indicate better efficacy of adding a Keap1-Nrf2 PPI inhibitor to the RAS inhibitor.